While the ADA recommends considering a GLP-1 receptor agonist or the addition of mealtime insulin, 3 the AACE/ACE algorithm additionally recommends SGLT-2 inhibitors and DPP-4 inhibitors as potential therapies that can be added to basal insulin, if they are not already incorporated into the medication regimen
The evidence base for allulose's metabolic effects is insufficient to support claims of GLP-1 agonist activity, and such characterizations would be scientifically inaccurate and potentially misleading
The truth is, while GLP-1s can help with weight loss , they work much slower and come with side effects , especially if youre not incorporating strength training and proper nutrition
SubQ adipose tolerates up to 3 mL per site without compromising absorption
While these average changes seem minimal, caution is warranted: if a patient has underlying high blood pressure or heart disease, even transient increases could be risky